Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$3.81 USD
-0.31 (-7.52%)
Updated Aug 28, 2025 04:00 PM ET
After-Market: $3.79 -0.02 (-0.52%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Alto Neuroscience, Inc.'s return on equity, or ROE, is -44.34% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.03%. While this shows that ANRO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ANRO 3.81 -0.31(-7.52%)
Will ANRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
NR7 appears for ANRO after 0.72% move
H.C. Wainwright Sticks to Their Buy Rating for Alto Neuroscience, Inc. (ANRO)
ANRO forms Pocket Pivot on August 26
ANRO forms Pocket Pivot on August 25
Is ANRO poised for gains? Pocket Pivot shows up after rocketing 8.64%